Rilmazafone
Rilmazafone (リスミー, brand name Rhythmy; developmental code 450191-S) is a water-soluble prodrug developed by Shionogi and approved in Japan for the treatment of insomnia and as a pre-anesthetic agent. It is not a benzodiazepine in the pharmacological or structural sense — the parent compound contains no diazepine ring and has no affinity for benzodiazepine receptors — but is converted inside the body into several active benzodiazepine metabolites, principally rilmazolam, which produce sedative and hypnotic effects.